NEWS & RESOURCES

Alpheus Medical closed an oversubscribed $52 million Series B financing round. The funds will support a Phase 2B randomized controlled trial evaluating the efficacy of SDT in patients with newly diagnosed glioblastoma (GBM)

“The early clinical results are very encouraging for advancing treatment options in patients with newly diagnosed glioblastoma, a disease with few effective therapies,” commented Walter Stummer, Professor and Director of the Department of Neurosurgery of the University Hospital Münster, Germany,

Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas The results from their first-in-human study demonstrated that median overall survival was doubled and progression-free survival improved 3-fold The Company's...

Alpheus Medical Treats First Patients in First-In-Human Clinical Trial for Novel High-Grade Glioma Brain Cancer Treatment Milestone arrives as the company closes a $14 million follow-on Series A financing round to expand the clinical program for high-grade gliomas,...

FDA Grants Alpheus Medical Orphan Drug and Fast Track Designations for Novel Sonodynamic Therapy for Brain Cancer.
The company is currently enrolling patients in a multi-center Phase 1 clinical trial for the treatment of recurrent glioblastoma (GBM)

Alpheus Medical Announces Formation of World-Class Scientific Advisory Board (SAB) to Support Development of Novel Treatment for Brain Cancer SAB to provide meaningful guidance as the company begins a first-in-human (FIH) clinical trial of their proprietary,...

Alpheus™ Medical, Inc, a privately held company developing a novel sonodynamic therapy (SDT) platform targeting solid body cancers, today announced it has closed $16M in Series A financing.